This pathway is the target of the combination of dabrafenib and trametinib, which in 2014, was approved for the treatment of cutaneous melanoma harboring V600E or V600K-BRAF mutation by the Food and Drug Administration. The gene discussed is BRAF; the disease is cutaneous melanoma.